Imbruvica Becomes 1st FDA-Approved Therapy for Graft-Versus-Host-Disease in Adults
The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone…